HUMAN AMYLOID IMAGING CONFERENCE

The 2021 edition of the conference has been cancelled. We look forward to seeing you in 2022!

HAI 2021

It is with the deepest regret I announce our decision to cancel the upcoming 2021 annual conference due to concerns related to the novel coronavirus (COVID-19).

We are truly sorry we will all miss out on seeing each other this coming year.

As we look forward to a great new edition in January 2022, we thank all attendees, presenters, and supporters!

Keith A. Johnson, MD
Massachusetts General Hospital/Harvard Medical School

2020 INTRODUCTORY NOTES and KEYNOTE PRESENTATIONS

2020 DIDACTIC SESSION PRESENTATIONS

ALZFORUM HAI2020 COVERAGE

Mobile app:
https://my.yapp.us/HAICONF

COUNTDOWN TO CONFERENCE

Day(s)

:

Hour(s)

:

Minute(s)

:

Second(s)

HAI Conveners

Keith Johnson, MD, Massachusetts General Hospital

William Jagust, MD, University of California, Berkeley

William Klunk, MD, University of Pittsburgh

Chester Mathis, PhD, University of Pittsburgh

Maria Carrillo, PhD, Alzheimer’s Association

HAI 2020 Theme Co-chairs

Tobey Betthauser, PhD, University of Wisconsin
Brad Christian, PhD, University of Wisconsin
Ansel Hillmer, PhD, Yale University School of Medicine
Milos Ikonomovic, MD, University of Pittsburgh
Laetitia Lemoine, PhD, Karolinska Institute
Beth Mormino, PhD, Stanford University
Melissa Murray, PhD, Mayo Clinic
Julie Price, PhD, Harvard Medical School
Gil Rabinovici, MD, University of California, San Francisco

HAI 2020 Young Investigator Award Judges

Michael Devous, PhD, Avid Radiopharmaceuticals
Robert Koeppe, PhD, University of Michigan
Michael Pontecorvo, PhD, Avid Radiopharmaceuticals
Christopher Rowe, PhD, Austin Health
John Seibyl, PhD, Invicro
Victor Villemagne, MD, Austin Health

HAI 2020 PROGRAM COMMITTEE

Olivier Barret, PhD, MIRCen, CEA
Tobey Betthauser, PhD, University of Wisconsin
Brad Christian, PhD, University of Wisconsin
Teresa Gomez-Isla, MD, Massachusetts General Hospital
Roger Gunn, PhD, Imperial College
Ansel Hillmer, PhD, Yale University School of Medicine
Kenji Ishii, MD, Tokyo Metropolitan Inst. of Gerontology
Milos Ikonomovic, MD, University of Pittsburgh
Clifford R. Jack, MD, Mayo Clinic
Robert A. Koeppe, PhD, University of Michigan
Laetitia Lemoine, PhD, Karolinska Institute
Mark Lubberink, PhD, Uppsala University
Beth Mormino, PhD, Stanford University
Melissa Murray, PhD, Mayo Clinic
Agneta Nordberg, MD, PhD, Karolinska Institute
Rik Ossenkoppele, PhD, VU University Medical Center Amsterdam
Denise Park, PhD, University of Texas
Julie Price, PhD, Harvard Medical School
Gil Rabinovici, MD, University of California, San Francisco
Susan Resnick, PhD, National Institute on Aging
Juha Rinne, MD, PhD, University of Turku
Stephen Salloway, MD, Brown University
Sandra Sanabria, PhD, Genentech
Reisa Sperling, MD, Brigham and Women’s Hospital
Rik Vandenberghe, MD, PhD, KU Leuven
Victor Villemagne, MD, The University of Melbourne
Sylvia Villeneuve, PhD, McGill University

OBJECTIVES

1.

Attendees will have the opportunity to review the basic, fundamental principles of amyloid and tau PET imaging, including radiochemistry and radio-tracer synthesis, PET acquisition and data processing, including application of corrections for the partial volume effect and co-registration with structural data. Particular attention will be given to the assessment of longitudinal PET data as it relates to methods of analysis and comparison to other domains of data, including structural and functional brain imaging data, and clinical and cognitive outcomes.

2.

Data analysis procedures discussed will include voxel-based and region-based approaches, masking for vulnerable regions, and choice of statistical procedures and specific use of control groups from older age groups.

3.

The concept of dichotomous versus continuous measures will continue to be extensively discussed, and the attendees should be able to characterize the advantages and disadvantages of both dichotomized and continuous variable approaches to analyses with respect to specific purposes or intended uses of the outcome.

4.

Attendees will have the opportunity to evaluate and compare amyloid and tau PET data in specific clinical and clinical research contexts, including review of typical findings in Alzheimer’s disease dementia, mild cognitive impairment due to Alzheimer’s disease, and in clinically normal individuals. These phenomena will also be related to familial forms of the disease and to non-AD processes such as fronto-temporal lobar degeneration and dementia with Lewy Bodies, and chronic traumatic encephalopathy.